26 Oct 2014

OMA RECOGNISES HOMOEOPATHY

OMA has sent out details of coming Toronto "HOMEOPATHY" courses at cost of $1.60 per mailing.:(:large brown envelope -with OMA crest- for a thin brochure). Homoeopathy is NOT a benefit of OHIP and so can be billed privately at free-market rates.Courses to held at WESTIN PRINCE HOTEL.in East Toronto.

Royal HOMOEOPATHS include

Classical Homoeopathy.
By Dr Margery Blackie CVO, MD, FFHOM.
Edited by Drs Charles Elliott and Frank Johnson.
Beaconsfield Publishers, Beaconsfield 1986.
Pp. 320.
9.50 pounds

Margery Grace Blackie 1898 – 1981

Margery Grace Blackie 1898 – 1981 was an orthodox doctor who converted to homeopathy to become the homeopath of Queen Elizabeth 

Margery Grace Blackie was born at Redbourn, Hertfordshire, England in 1898. She qualified in medicine at the London School of Medicine for Women in 1923, and in the following year joined the staff of the London Homeopathic Hospital.
 She obtained her M.D. from the London School of Medicine for Women in 1923.
During her career she combined a busy homeopathic general practice with her hospital work, which culminated in her appointment in 1966 as Honorary Consultant Physician to the Royal London Homeopathic Hospital.
She was Dean of the Faculty of Homoeopathy from 1965 to 1979. She was appointed Physician to Queen Elizabeth II in 1968.
 Homeopathic pioneer Margery Blackie was commemorated with an English Heritage Blue Plaque on 12 October at 3pm at 18 Thurloe Street, London, SW7 where the homeopathic physician lived and worked from 1929 to 1980. The Blue Plaque was unveiled by HRH Princess Alexandra.
Margery Blackie was born in Hertfordshire in 1898, the daughter of a leading homeopath. At the age of five Blackie declared that she wanted to become a doctor, such was the influence of her uncle James Compton Burnett, a leading homeopath himself, and his work upon her.
Blackie entered the London School of Medicine for Women in 1917 and before qualifying became a Resident at the London Homeopathic Hospital. Her experiences at the hospital confirmed her belief in homeopathy, and in 1926 she set up her own practice in Kensington. Here, she developed sound consulting room methods and encouraged patients to tell their story in their own way, while also making a clinical diagnosis of her patients, using conventional methods such as x-rays and pathological tests. Her aim was simple – to understand her patients as deeply as possible.
During the 1930’s, Blackie continued to work at the London Homeopathic Hospital, but spent most of her time developing her own practice. Her flair for diagnosis had become legendary. Patients included a number of public figures such as Julia Myra Hess and Julia de Beausobre Lady Namier.
In 1949, Blackie was elected President of the revitalised Faculty of Homoeopathy. This was a major achievement; she was the only woman office holder in the Faculty – and marked a phase in her life. She took the lead amongst her British colleagues and mixed frequently with homeopaths from all over the world.
In 1964, Blackie was elected Dean of the Faculty of Homoeopathy, with responsibility for all teaching. It was from this position that Blackie influenced a whole generation of homeopathic doctors.
In 1969, in a moment which marked the climax of her career, Blackie was appointed Physician toQueen Elizabeth II. By the mid-1970’s, Blackie’s own health was in decline, but she continued to see patients at 18 Thurloe Street, London, SW7 until 1980, when she left London to retire to Hedingham Castle in Essex. It was there that she died on 24 August 1981.
18 Thurloe Street, London, SW7 was ideally suited to Blackie and served as her home as well as her consulting room. It had a homely atmosphere, and there was always an open fire in the consulting room to welcome patients, students and homeopaths, who would travel from all over the world to sit in during her surgeries.


Dr. Margery Blackie and Sir John Weir
Dr. Margery Blackie and Sir John Weir





Sir John Weir, GCVO, Royal Victorian Chain (19 October 1879 – 17 April 1971), MB ChB Glasgow 1907, FFHom 1943, Physician Royal to several twentieth century monarchs.
Born in the town of Paisley, in Renfrewshire, Scotland, Dr Weir was to become Physician Royal to King George V (reigned 1910–36; Weir his physician from 1918), King Edward VIII (reigned 1936), King George VI (reigned 1936–52), Queen Elizabeth II (physician 1952-68), and King Haakon VII (1872–1957) of Norway, whose wife Maud (1869–1938) was the youngest daughter of King Edward VII (1841–1910).
Weir attended Allan Glen's School in Glasgow, a school noted for its emphasis on science. He received his medical education first at Glasgow University MB ChB 1907, and then on a sabbatical year in Chicago under the tutelage of Dr James Tyler Kent of Hering Medical College during 1908-9, along with Drs Harold Fergie Woods (1883–1961) and Douglas Borland (1885–1961).
He returned to the London Homeopathic Hospital as Consultant Physician in 1910, and was appointed the Compton-Burnett Professor of Materia Medica in 1911. He rose to become President of the Faculty of Homeopathy in 1923.

He spoke on homeopathy before the Royal Society of Medicine in 1932, and was knighted by King George V that same year. The renovated Manchester Homoeopathic Institute and Dispensary was opened in Oxford Street by Sir John Weir in May 1939. Weir said in an “address: homeopathy…is no religion, no sect, no fad, no humbug…remedies do not act directly on disease; they merely stimulate the vital reactions of the patient, and this causes him to cure himself.” [Sir John Weir, 1931, 200-201]

Having advanced through all levels of the Royal Victorian Order he was, as a rare distinction, awarded the Royal Victorian Chain in 1947, possibly as a mark of the medical care he gave to the ailing King George VI.

23 Oct 2014

TORONTO: HOSPITALS SECURITY DEFICIT

(BLOG COMMENT)
Unlike in USA, Toronto Hospitals have no security control at entrances or requirement of a visitor badge to be admitted to in-patient floors. Some e.g. Toronto General and Toronto Western havemany  retail food vendors and shops. In Toronto Western lobby the arm chairs are used as sleeping facilities by local "homeless": with their bags.Toronto East General  and St Joseph Hosp.have least entrances and retail stores.

17 Oct 2014

OMA COMPLEMENTARY MEDICINE MEETING: Jackson Hall of Art Gallery Ontario 16 Oct.: Conservative MP (Oakville) Terence YOUNG on proposed punitive federal legislation on Pharmaceutical Executives.(incl 2 years prison).

At the meeting MP T.YOUNG  said that Bill C-17 which began as`a Private member's Bill is now backed by Fed.MOH Hon Ronalee Ambrose PC..

According to Mr Young, his 15y daughter Vanessa suffered from BULIMIA (Nervosa). For some reason a local MD prescribed cisapride (Prepulsid) a`serotonin receptor agonist which increases acetylcholine release
in the enteric nervous system. Prepulsid was indicated for GERD & diabetic gastroparesis.'.Mr Young said he knew that the prescription was "off label" : there was no indication for use in children with bulimia.

Vanessa died in hospital from arrhythmia .It was known that Prepulsid was a drug that could prolong Q-T interval. 2.5% of popn have prolonged Q-T. 10-15% with LQTS (Long Q-T syndrome) have normal ECGs. LQTS can be an inherited condition: usually AUTOSOMAL DOMINANT. . TORSADE de POINTES is a complication.

Mr Young did not say whether his daughter had been treated by a Paed. psychiatrist or attended an Eating disorder clinic.Bulimia nervosa,"an ominous varient of Anorexia nervosa" first described by UK Psych Prof . G.F.M. RUSSELL BMBCh(Edin 1950) FRCP in PSYCHOLOGICAL MEDICINE.

Psychol Med. 1979 Aug;9(3):429-48.

Bulimia nervosa: an ominous variant of anorexia nervosa.

Abstract

Thirty patients were selected for a prospective study according to two criteria: (i) an irresistible urge to overeat (bulimia nervosa), followed by self-induced vomiting or purging; (ii) a morbid fear of becoming fat. The majority of the patients had a previous history of true or cryptic anorexia nervosa. Self-induced vomiting and purging are secondary devices used by the patients to counteract the effects of overeating and prevent a gain in weight. These devices are dangerous for they are habit-forming and lead to potassium loss and other physical complications. In common with true anorexia nervosa, the patients were determined to keep their weight below a self-imposed threshold. Its level was set below the patient's healthy weight, defined as the weight reached before the onset of the eating disorder. In contrast with true anorexia nervosa, the patients tended to be heavier, more active sexually, and more likely to menstruate regularly and remain fertile. Depressive symptoms were often severe and distressing and led to a high risk of suicide. A theoretical model is described to emphasize the interdependence of the various symptoms and the role of self-perpetuating mechanisms in the maintenance of the disorder. The main aims of treatment are (i) to interrupt the vicious circle of overeating and self-induced vomiting (or purging), (ii) to persuade the patients to accept a higher weight. Prognosis appears less favourable than in uncomplicated anorexia nervosa.



(The following is a full text of Terence’(YOUNG) speech.)
Mr. Speaker I am very pleased to stand here in the Parliament of Canada today to endorse Vanessa’s Law, the Protecting Canadians from Unsafe Drugs Act.
I am honoured to be a member of the first Canadian government ever to tackle the insidious and largely hidden problem of the injuries and deaths routinely caused by prescription and over-the counter drugs.
I thank two consecutive Ministers of Health, and our Prime Minister who have acted boldly to make Canadians safer, directly taking on the most influential industry in the world, Big Pharma, and the status quo in the practice of medicine, which has been corrupted by that industry.
Today is a milestone for me and the Young family, as well as one for the Government of Canada.
I stand here today due to a tragedy in our family that took place exactly fourteen years ago last week, on Saturday March 18, 2000.
Without warning, our fifteen year old daughter Vanessa—for whom this act is named—fell down dead in front of me, her heart stopped by the Johnson and Johnson blockbuster prescription drug Prepulsid, a drug we later discovered she should never have been given.Despite emergency ambulance services and valiant efforts of doctors at two hospitals, Vanessa never regained consciousness and died the next day.
We never had a chance to say goodbye.
On March 20, 2000 I began the journey that led me to the House of Commons this morning.
The facts of this tragedy shock every lay-person who hears them. Yet I was to quickly discover the insiders: doctors, researchers, and people at Big Pharma were never shocked. They knew all along that potentially life threatening drugs were being pushed on patients with non-life threatening conditions, as the drug business had become all about Wall St. And they were all benefiting financially, big time.
Our doctors are groomed through highly sophisticated Big Pharma relationship marketing programs and get their first free lunch the first week of medical school. They go on to naively accept up to $ 4 billion a year in North America in gifts, lunches, dinners, event tickets and free trips from drug companies, imagining these debts of gratitude don’t change their prescribing behaviour. Sometimes I’d ask them, “Do you think the drug company takes doctors to Bahamas out of kindness?”
They also accept and hand out – without any prescription – $3 Billion a year worth of free samples of new prescription drugs, creating debts of gratitude in their own patients; a dangerous practice because patients get no safety warnings. In November 2010 eighteen year old Brennan McCartney of Bolton, Ontario took a free sample of antidepressant Ciprolex with no safety warning for suicide which is written right on the drug’s label, and went out and hanged himself from a tree in a public park.
Four doctors knew Vanessa was taking Prepulsid for bloating and a mild form of bulimia. Yet neither Vanessa nor we, her parents, were given any warning that the drug was already responsible for 80 deaths. Why?
How could this happen to the beautiful innocent child her doctor described as “the picture of perfect health?” How could four doctors, people we totally trusted, allow Vanessa to continue taking a drug that could stop her heart?
I began the next day to find out how Vanessa died, and why, and uncovered many dark secrets.
Prescription drugs taken as prescribed, the right way, are the fourth leading cause of death in North America — over 106,000 deaths a year just in hospitals. Another 100,000 occur outside hospitals. That’s about 20,000 deaths a year in Canada, with 200,000 drug injuries.

What They Never Talk About

The drug industry representatives who infest parliament hill love to talk about when doctors make errors, or patients take the wrong drug, or too much of a drug.
What they never talk about is when a drug used the right way injures or kills a patient, causing 10,000 deaths a year in Canada.
In fact one in nine patients in Canada suffer serious drug reaction in hospitals.
1. All drugs are poisons. Any drug can be toxic. It’s just a matter of dose. And all drugs cause adverse effects. Some people think OTC drugs are totally safe. Yet ordinary Acetaminophen (Tylenol) causes hundreds of deaths every year, and more cases of acute liver failure than all other medications combined. Too much taken with alcohol, and it can destroy one’s liver.
Yet has your doctor ever mentioned that?
Ordinary aspirin and Ibuprofen cause thousands of deaths every year across North America, mostly by internal bleeding. Yet most patients have never heard this. Why not? There is only one reason: Because the people that market them — Big Pharma — don’t want patients to know the truth. That would reduce sales!
What happened to Vanessa, and Brennan McCartney, could happen to anyone who takes drugs without proper safety warnings. Nothing significant has changed since 2000 except the current introduction of plain language labelling for drugs, and this Bill.
Vanessa’s Law will empower the Minister of Health to compel drug companies to change their labels to clearly reflect the true risks to patients from their drugs, so patients can make an informed decision to take that drug... or not. Patients can then take drugs only when they are relatively safe.
2. Twenty seven drugs have been pulled off the Canadian market since 1997 for injuring and killing patients. Propulsid is one. Another, painkiller Vioxx, killed 55,000 to 65,000 patients worldwide in four years on the market. Why don’t most Canadians know that? Because the drug companies never admit their drug harmed anyone; they spends months and months investigating serious reactions. Then they attempt to blame the patient, concluding –
“He must have taken too much;”
“She must have had a previous undiagnosed and unknown condition;”
“It must have been the combination of our great drug with the other drug he was taking. We hereby contraindicate our great drug with their drug.”
So they change the fine print on the 50-page label that few doctors and even fewer patients ever read.
Then they carry on promoting it, often off label, which means for conditions it has never been proven safe or effective.
Doctors can prescribe any drug, at any time, for any condition, for any patient, even if it’s never been proven safe for such use. In fact, 70% of doctors prescribe off-label sometimes. Modern medicine is the Wild West.

That’s what the Johnson and Johnson detail reps did to Vanessa’s doctors. They whispered to them that Prepulsid was effective for teens that threw up after meals. Yet it was contraindicated, dangerous for anyone throwing up. That was the official warning. But they didn’t whisper that in her doctor’s ear. Because Prepulsid was heading for blockbuster status: the golden calf: a billion dollar a year drug!
And Just before Health Canada is about to take action to expose the risks, the drug companies will pull deadly drugs off the market “voluntarily.” That way they can keep selling them in over a hundred other countries in the world – because they never admitted their drug caused any harm.
That’s the drug business.
Vanessa’s Law will give the Minister of Health the power to order drugs that present a serious or imminent risk of injury or death off the market without delay. Had this been done with Prepulsid, instead of negotiating over weeks with Janssen-Ortho, Prepulsid would have been recalled.
Vanessa would be alive today, along with many others.
3. Drug companies refuse to provide the true number of serious adverse drug reactions to health Canada. They report what they hear about, but what does NOT appear on the label is this crucial fact: only 1% of serious adverse drug reactions are actually reported by doctors. Most doctors have never reported an ADR! In fact, outside of the doctors I’ve met who specialize in drug safety, I’ve never met a doctor who reported an ADR. And despite my advocacy in this matter for 14 years – that reporting adverse drug reactions saves lives by providing a widely based early warning system for dangerous drugs – the Canadian Medical Association and Ontario Medical Association to this day do not support making adverse drug reaction reporting a standard practice or mandatory.
Doctors are fooled by their own negligence in not reporting lifesaving information. Patients die as a result.
On October 9, 2011 eighteen year old Allison Borges of Oakville was found in a stairwell of her residence at Queen’s University dead, having suffered a pulmonary embolism caused by a birth control pill her doctor told her was safe. She received no warning that the newer birth control pills are more likely to cause deadly blood clots than the older ones. No woman should be given a birth control pill without a clear warning of deadly blood clots. Yet it happens all the time. Sadly, 18 year old Merit McKenzie of Calgary suffered the same fate in January 2013. Vanessa’s Law, if implemented, would have prevented these two tragic deaths.
Vanessa’s Law wil, for the first time, impose a duty on healthcare institutions to report all serious ADRs, which will capture any ADR that causes the patients to end up in a hospital or clinic. That will hopefully capture the majority of serious ADRs, so officials can be alerted to dangerous drugs faster. This will help get them off the market faster and save lives. We must rely on the provinces to persuade doctors to stop covering up adverse drug reactions caused by their prescriptions.
4. Over half of the serious side effects of new drugs won’t be revealed during testing. In fact, in the first two years on the US market, one in five –20%– of new drugs will be pulled off the market for injuring or killing patients, or be assigned the highest level of warning – a Black Box warning to be handed to each patient with their prescription – a more effective warning Canada has never had.
In May 2007 18 year old Sara Carlin of Oakville stopped taking her prescription antidepressant Paxil abruptly, then doubled up, to catch up two days later. She had no warning that Paxil could cause suicidal ideation and akathesia in those circumstances. Her father found her the next day, hanged by her own hand in the basement of their home. Neither Sara nor her family heard about the five Dear Doctor letters warnings that Health Canada had sent out about Paxil.
Vanessa’s Law will for the first time allow the Minister to order an new assessment of a drug, including conducting tests or studies and report them to Health Canada – to change the drug label to better reflect the newly identified risks.
Proposed regulations for drug labelling will empower Health Canada to order drug companies to issue labels and patient information leaflets that are written in plain language with the rare but dangerous potential side effects listed up-front on page one, so doctors and patients can decide if the true dangers are worth risking treating their condition.
5. In 2003 Dr. Allan Roses, World-Wide Vice President of genetics at GSK – the world’s second largest Big Pharma company – made this statement at a scientific meeting, not knowing a journalist was present: “The vast majority of drugs, more than 90%, only work in 30 or 50% of people.” What this means is, with a worldwide market of $800 billion for prescription drugs, as much as $400 billion a year is not only wasted on drugs, but millions of patients are exposed to the dangers with no chance of benefitting. According to The Canadian Pharmacist Association between $2 billion and $9 billion is wasted in our drug system every year. This means that as patients increasingly reject the drug industry’s pill for every ill, our health care system will save billions of dollars, hopefully to be invested in preventative care.
Mr. Speaker, 70% of adverse drug reactions are preventable. They are caused by the aggressive over-marketing of drugs, the misleading sales pitches, and the covering up of harms that victimize patients.
How could any moral corporate executive push a drug that could stop a child’s heart to treat bloating? Because that’s exactly what the executives at Johnson and Johnson’s drug arm Janssen-Ortho did. And they broke the law doing it. This is quite normal in the drug business.
Drug safety is about one thing: Does the potential risk of this drug outweigh the potential benefits for me? Yet the Big Pharma companies do everything they can to make sure patients have no way to know the answer to this question. They exaggerate the benefits, and hide the risks.

Does This Sound Outrageous?

I know this sounds outrageous. It sounds like a father who lost his daughter AND has lost his objectivity.
So let me give you just a few factual examples of hundreds, where Big Pharma companies have openly admitted to crimes to increase sales of their drugs:
In 2012 GSK — the people who made our H1N1 vaccine in Canada — paid a fine of $3 billion, the highest in history, to US governments for illegally marketing three drugs: Paxil, an anti-depressant which causes suicides, Avandia, a diabetes drug that causes heart attacks and strokes, and Wellbutrin, another antidepressant which causes suicides.
Yet GSK had grossed $26 billion in sales for these three drugs in the previous six years. And with markups in drugs in the hundreds and thousands of percent, a $3 billion fine was just a cost of doing business for GSK. Like paying a parking ticket.
Shortly after Vanessa died I asked ADR expert Dr. Neil Shear why drug companies don’t just take dangerous drugs like Prepulsid off the market. He replied “In the drug industry, killing people is not bad for business. As long as it’s not too many.” Nothing has changed since that time.
Big Pharma companies put the legal costs from injuries and deaths right in their business plans.
Here are some more examples of Big Pharma corporate crimes:
  • Merck has paid $1.6 billion in settlements since 2008 in part for paying illegal kickbacks to health care providers;
  • Ely Lilly paid $ 1.3 billion in 2009 for illegally promoting Zyprexa, leading to the deaths of many seniors;
  • Novartis paid $422 million in 2010 for off-label promotion of Trileptal;
  • Forest Labs paid $313 million in 2010 for off-label promotion of Celexa and Levothyroid;
  • Allergan paid $825 million in 2010 for off-label promotion of Botox;
  • AstraZeneca paid $520 million in 2010 for misleading doctors and patients about the safety of Seroquel;
  • Johnson and Johnson paid $81 million in 2010 for off-label promotion of Topomax;
  • Elan paid $203.5 million in 2010 for illegally marketing Zomegran;
  • Sanofi-Aventis paid $ 96.5 million in 2009 for illegal pricing of a nasal spray;
  • Abbott paid $22.5 million in 2010 for blocking 23 states from getting a cheaper alternative for Tricor;
And these offences are just some of those that occurred since 2008.

How do they get away with all this?

Power. And influence. They are some of the wealthiest companies in the world, with no loyalty to any country.
And above all else, despite the thousands of deaths, no Big Pharma executive ever goes to jail. Imagine if murderers, or rapists, or extortionists could simply negotiate payments with some government official to keep out of jail... and keep on doing what they have been doing.
The only way these companies will ever stop their corrupt practices is (1) if the practices become unprofitable... and (2) if those responsible face real jail time.
So Vanessa’s Law for the first time will impose tough new penalties for unsafe products, increasing fines from $5,000 a day to $5 million a day and include jail time for up to two years. That’s the only way to actually get their attention and change their ways.
And if these serious violations are caused intentionally, court imposed fines could be unlimited. My hope is that, when life threatening dangers were intentionally covered up, judges will fine offenders like this the entire amount of their sales of a blockbuster drug or more. Nothing less will change their practices.
Mr. Speaker, Vanessa’s Law is the beginning of the end for the unscrupulous and corrupt marketing practices in the Big Pharma companies in Canada. It will no doubt reduce drug injuries and deaths in Canada by thousands. It is much needed and long overdue.

We can never have Vanessa back in this life; or Sara Carlin; or Alison Borges; or Brennan McCartney; or Merit McKenzie.
But we can change things moving forward. We can do what governments are supposed to do: protect vulnerable people. Vanessa’s Law represents the highest calling of a government. When the death of an innocent child can lead to definitive action by the government of Canada to help prevent others from the same fate, our democracy is at its best.
Mr. Speaker, every school day across Canada millions of school children sing “From far and wide, Oh Canada, we stand on guard for thee.” But that promise has to be a two way street!
Vanessa Young would be proud to see that, with Bill C-17, Canada is standing on guard for its school children, and seniors, and other vulnerable patients.

(Comment: no mention of prescriber)





15 Oct 2014

Toronto Univ.Health Network Pres.&CEO Surgical Oncologist Peter PISTERS MD(U.West.Ont.) Master Health Management (Harvard) FACS

UHN’s Board Chair announces new CEO



​​​Image of Dr. Peter Pisters
Dr. Pisters says returning to Canada as President & CEO of UHN is a​ challenge and a privilege.​​
​ I am very happy to be able to send this message and tell you that we have concluded our international search for UHN's President  & CEO and that Dr. Peter Pisters will be joining us on January 1, 2015.  UHN's Board of Trustees and the Selection Committee knew how important it was to find someone who understood and was committed to superb clinical care, world-class research, and a teaching environment that supports and encourages all members of UHN's community.  We also know that we had to find someone who was completely committed to our efforts to have our patients know that they are partners in their care.
I speak for all members of the Board and the Selection Committee when I say that we have found that person in Peter.
Dr. Pisters is currently the Vice President, Regional Care System at the University of Texas MD Anderson Cancer Center in Houston Texas.  He is an internationally known academic surgical oncologist with a specialty focus in sarcoma and gastrointestinal cancers, and an Executive Fellow (2014-15) in the Baldridge Performance Excellence Program of the U.S. Department of Commerce National Institute of Standards and Technology.  Dr. Pisters is a graduate of The University of Western Ontario (MD) and Harvard University School of Public Health (M.Sc. in Health Care Management).  He was Chief Administrative Fellow in the early nineties at Memorial Sloan-Kettering Cancer Center and prior to that his internship and residency were completed at New York University Medical Center – Bellevue Hospital.
So – as you see from his medical degree, Peter is Canadian and is returning home after an extraordinary career in the U.S.  I know that Peter and his family are very excited about the move that means that Peter will now lead Canada's pre-eminent research hospital.  In the coming months he will be in Toronto to find a home and begin the task of getting to know UHN and all of the people that make this organization such a special place.  You will find him warm, easy to talk to and committed to making this the very best place for care, while supporting our people to be the best they can be.
Justine Jackson will continue as Interim President & CEO and I know that I also speak for everyone on the Board to say that Justine is doing a wonderful job in ensuring that UHN remains stable during this period.  In fact, I can say that Justine has done much more than maintain stability – she has been pushing forward on a number of fronts and I know that she will be invaluable to Peter, as will all members of the senior team.
I would like to thank all members of the Selection Committee for their commitment to this process and all members of the Board of Trustees for their support and encouragement throughout.  And I would ask that every member of the UHN team join with me in congratulating Peter on his appointment and welcoming him home.

​ John Mulvihill
Chair of the Board of Trustees
​University Health Networ

Present Title & Affiliation

Primary Appointment

Vice-President, Regional Care System, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement


Peter W.T. Pisters, MD, MHCM, CPE, FACS, FACHE
University of Texas MD Anderson Cancer Center

Regional Care System
Houston, TX, USA
Dr. Peter W.T. Pisters is an academic surgeon and physician executive at The University of Texas MD Anderson Cancer Center. As, a Professor of Surgery, Dr. Pisters has clinical experience and academic interest in gastric cancer, pancreatic cancer, and soft tissue sarcomas. Dr. Pisters has held leadership positions in national medical organizations and cooperative groups dedicated to advancing the science and treatment of cancer. He is also a member of the editorial board of multiple surgery and oncology journals and has authored more than 200 peer-reviewed publications and 70 book chapters.

 As Vice President and Medical Director of MD Anderson’s Regional Care System, Dr. Pisters provides leadership and direction in areas that include strategy, business development, and operations for MD Anderson’s regional operations.   These regional care centers are clinically integrated with MD Anderson’s Texas Medical Center campus and provided services for 5200 new cancer patients in FY12.

Office Address

The University of Texas MD Anderson Cancer Center
7007 Bertner Avenue
Unit 1639
Unit Number: 1407
Houston, TX 77030
Room Number: 1MC10.2206
Phone: 713-794-1572
Email: ppisters@mdanderson.org

Education & Training

Degree-Granting Education

2014 Harvard University School of Public Health, Boston, MA, MS, Healthcare Management
1985 University of Western Ontario, London, Ontario, Canada, MD, Medicine

Postgraduate Training

7/1993-6/1994 Chief Administrative Fellow, Surgical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, Murray F. Brennan, M.D.
7/1992-6/1994 Clinical Fellowship, Surgical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, Murray F. Brennan, M.D.
7/1989-6/1992 Senior and Chief Resident, General Surgery, New York University Medical Center-Bellevue Hospital Center, New York, NY, Frank C. Spencer, M.D.
7/1987-6/1989 Research Fellowship, Surgical Metabolism Laboratory, Memorial Sloan-Kettering Cancer Center, New York, NY, Murray F. Brennan, M.D.
7/1985-6/1987 Intern and Junior Resident, General Surgery, New York University Medical Center - Bellevue Hospital Center, New York, NY, Frank C. Spencer, M.D.

Board Certifications

2013 American Board of Surgery

Experience/Service

Administrative Appointments/Responsibilities

Clinical Consultant, The University of Texas M. D. Anderson Cancer Center, Center for Global Oncology, Houston, TX, 7/2008-present
k


14 Oct 2014

U.Toronto mag. ignores pre-and postnominals with exception of "Prof."

For a mag. representing the U.Tor. it was laughable to read the piece by Claire Morris & Michael Kennedy about the $10-mill. donation by "Michael & Amira Dan".for an "Institute for Indigenous Health ". The scribes omitted all the pre & post- nominals of Neurosurgeon & Private equity investor Dr. Michael Dan MD(Tor.) PhD (McGill) MBA (Tulane) FRCS(Can.) DABNS (USA)

It has been the magazine’s policy for many years to omit all titles other than “Prof.” to indicate someone associated with the university. Thank you for writing,

Janet Rowe
Acting Deputy Editor, U of T Magazine

Dear Ms ROWE,
Prenominal "Prof" fine, what about "DR"?
Also what about earned academic postnominals?

we also do not include these elements in the magazine. Sincerely,

 Janet Rowe
Acting Deputy Editor, U of T Magazine

13 Oct 2014

Globe & Mail: Federal Health Minister 45y Hon.RONALEE AMBROSE PC MP (Edmonton-Spruce Grove) will use Nurses to screen air passengers from West Africa.

Fed. Min. Health Ronalee ("Rona") AMBROSE BA( U.Victoria, BC) MA Pol.Sci.(U.Alberta, Edmonton) Married to ScotiaMcLeod Branch Manager, Edmonton. Bruce AMBROSE.

"Min Ambrose acknowledged the (temperature)screening may not be effective if a person has no symptoms "Globe & Mail.

(No mention of blood and urine tests. Also no mention of using MDs trained in Tropical medicine.)

12 Oct 2014

UK PRIVATE EYE # 1376: BIRMINGHAM NHS RESTRICTS OUT-OF-AREA PATIENTS to DEPTS. of PAIN, DERMATOLOGY & GENERAL SURGERY.

"August 26 Andrew McKirgan, executive chief operatng officer of University Hospitals Birmingham NHS Foundation Trust sent a blunt letter to the chiefs of clinical commissioning groups (CCGs) who are outside the area....we are no longer in a position to combine patient choice with a guaranteed maximum 18-wk waiting time."

"NHS in England alone is facing a GBP30bn deficit over the next five years."

11 Oct 2014

CASSELS BROCK: Award to employee after 10 years.following dismissal.


Cassels Brock e-LERT | October 2014





EMPLOYMENT & LABOUR
E-LERT

 OCTOBER 2014 casselsbrock.com
Surprising Reinstatement Decision of the Human Rights Tribunal Upheld
By
:
 Geoffrey Breen

You may recall that last year, the Ontario Human Rights Tribunal (“the Tribunal”) raised the eyebrows of employers when it ordered that a terminated employee be reinstated to her position with full seniority almost a decade after she had left the workplace. In Fair v. Hamilton-Wentworth District School Board, 2013 HRTO 440 (“Fair”), the employee was awarded, among other things, reinstatement (which included nine years of back pay) and $30,000 for compensation for the injury to her dignity, feelings and self-respect. To read our prior e-lert on this decision, click here.

Until recently, the Tribunal had generally been of the view that its reinstatement powers should be exercised in limited circumstances. As a result, many were surprised to see the Tribunal reinstate an employee almost ten years after her termination. Such a decision results in an uncharacteristically large damages award and also leaves the employer with the undoubtedly uncomfortable task of re-integrating the employee back into the workplace.

It was therefore no surprise that the employer in Fair brought an application for judicial review of the Tribunal’s decision before a panel of the Ontario Superior Court of Justice, Divisional Court (“Divisional Court”). Among the several grounds raised, the employer challenged the appropriateness of the reinstatement award in the circumstances.

On September 29, 2014, the Divisional Court released its decision on the application,1 upholding the decision of the Tribunal and awarding an additional $15,000 in costs against the employer in respect of the judicial review process.

The Divisional Court made short order of the employer’s quarrel with the reinstatement award. It held that the Tribunal has broad remedial authority and that, while reinstatement is unusual, there is no barrier or obstacle to the remedy at law. The Divisional Court concluded that the Tribunal’s decision with respect to remedy is “intelligible, transparent and with justification. The outcome is within the range of reasonable expectation.”

While one could argue that such a result was not within anyone’s reasonable expectation at the time, with Court approval of the Tribunal’s decision in Fair, employers should now have little doubt that the Tribunal’s power to reinstate is a risk on any termination that is found to result from unlawful discrimination.
__________________________

1 Hamilton-Wentworth District School Board v. Fair, 2014 ONSC 2411